Can You Test for GHB and How Long Is It Detectable?

GHB can be tested for, but detecting it is far harder than detecting most other drugs. The compound is cleared from blood in roughly three hours and from urine within about six to twelve hours, which means standard hospital drug screens almost always miss it entirely. Hair analysis can push that window out to weeks or even a month, though it requires specialized techniques unavailable at a typical emergency department. The short answer is that testing exists, but timing, sample type, and laboratory capability all have to align for it to work.

Why GHB Disappears So Quickly

GHB has an unusually fast metabolism. After someone swallows it, blood levels peak within about 20 to 40 minutes. The body then eliminates it with a half-life of roughly 30 to 50 minutes, meaning concentrations drop by half every half hour or so. Only about one to five percent of the dose ever makes it into urine, which is why urine testing has such a narrow window compared to other recreational drugs.¹ In a controlled study where volunteers received a single therapeutic dose, all twelve had blood levels below 5 mg/L within three hours.²

Compare that to something like cannabis, which can remain detectable in urine for days or weeks, or cocaine metabolites that linger for two to three days. GHB’s detection window of a few hours makes it an outlier. This rapid clearance is why forensic toxicologists consistently stress that samples must be collected as soon as possible after suspected exposure.

Detection Windows by Sample Type

How long GHB remains detectable depends heavily on what you’re testing.

Blood: GHB is typically detectable for about three hours after a single dose. Blood levels peak within 20 to 25 minutes and decline steeply after that.²
Urine: The commonly cited window is about 6 to 12 hours. In one study of 16 adults given a therapeutic dose, nearly all urine samples collected between 6 and 12 hours had already fallen below the standard cutoff used to distinguish drug use from the body’s own natural GHB production.³ That study actually concluded the real window may be shorter than twelve hours for some people taking standard doses.
Oral fluid (saliva): Similar to blood in terms of window. Oral fluid has endogenous GHB present at baseline, so interpretation requires the same careful cutoff approach as urine.⁴
Hair: GHB can be detected in hair weeks after exposure, even from a single dose. Hair collection typically happens about a month after the suspected event, once the relevant segment has grown out far enough to be cut and analyzed separately.⁵

These windows assume a single recreational or therapeutic dose. Higher doses or repeated use can push detection times somewhat longer. In one documented case, an elderly woman had GHB detected in her urine more than 24 hours after ingestion, likely because of a very large dose combined with age-related changes in metabolism.⁶ But that kind of extended window is unusual enough to be published as a case report.

Standard Hospital Drug Screens Will Not Find It

One of the most important things to understand is that the urine and blood drug screens used in most emergency departments do not test for GHB at all. These panels are designed to flag common drugs of abuse like opioids, amphetamines, benzodiazepines, and cannabis. GHB requires a separate, targeted analysis using specialized equipment. A case report in 2025 illustrated this vividly: a patient arrived at the hospital with altered consciousness and respiratory depression consistent with GHB overdose, but his standard drug screen came back showing only methamphetamines. GHB was responsible for the most dangerous symptoms, yet the initial workup missed it entirely.⁷

If you suspect GHB exposure, you or your medical provider need to specifically request GHB testing. Even then, not every hospital lab can run it. The sample often has to be sent to a reference laboratory or forensic toxicology lab, which adds time. Given the narrow detection window, this creates a frustrating Catch-22: by the time results come back, the drug may already have cleared the system. Asking for the sample to be collected and preserved early, even before results are expected, gives the best chance of capturing evidence.

The Endogenous GHB Problem

Your body naturally produces small amounts of GHB as a byproduct of normal brain chemistry. GHB is formed during the breakdown of GABA, the brain’s main inhibitory neurotransmitter.⁸ This means there is always a small, measurable amount of GHB in blood and urine, even in someone who has never been exposed to the drug. In a placebo-controlled clinical trial, endogenous GHB in blood ranged from about 0.007 to 0.05 micrograms per milliliter, and in urine from about 0.016 to 0.41 micrograms per milliliter.⁴

This baseline means forensic labs cannot simply report “GHB detected” and call it proof of drugging. They need a cutoff, a threshold above which the concentration is considered too high to be naturally occurring. The commonly used cutoff in urine is 10 mg/L. Below that, results are treated as potentially endogenous. Above it, exogenous administration is suspected. But this creates a gap: once the drug has partially cleared but hasn’t quite reached background levels, the measurement can land in an ambiguous zone that is hard to interpret legally.

Hair Testing as a Longer Window

When blood and urine are no longer viable options, hair offers the most realistic path to documenting past GHB exposure. As hair grows, substances circulating in the bloodstream get incorporated into the hair shaft. Since hair grows at roughly one centimeter per month, forensic analysts can cut the hair into segments and determine approximately when a drug was present in the body.

In controlled experiments, a single dose of GHB was detectable in hair when the relevant segment was analyzed about a month after exposure. In an actual sexual assault case, the hair segment corresponding to the time of the assault showed GHB levels roughly three to four times higher than surrounding segments, providing clear evidence of a spike.⁵ More recent work has pushed the technique further, analyzing individual hairs in 2-millimeter segments to get even finer time resolution.⁹

Hair testing has its own complications, though. Everyone’s hair contains low levels of endogenous GHB, just as blood and urine do. The interpretation relies on comparing segments to each other: if one segment shows a clear spike above the person’s own baseline, that supports the conclusion that an external dose was taken during the time that segment was growing. Validated methods now detect GHB in hair down to 0.1 to 0.5 nanograms per milligram, which is sensitive enough to pick up a single recreational dose.¹⁰ The downside is the mandatory waiting period: you generally need to wait at least a month after exposure before collecting the hair sample, since the relevant section has to grow out past the scalp.

Drink-Spiking Test Kits

Consumer products marketed as GHB-detecting strips or pads for beverages have been around for years, but their reliability has been mixed. A recent lab evaluation tested both first-generation and newer second-generation devices. Older products were often insensitive, requiring GHB concentrations of 3.2 to 16 mg/mL to trigger a result, and two first-generation products failed to detect GHB even at 16 mg/mL. Colored drinks like whiskey, beer, and red wine also produced color changes that made reading the results unreliable.¹¹

The newer second-generation tests performed much better, detecting GHB at concentrations as low as 0.5 mg/mL, which the researchers considered sensitive enough to flag levels that could cause harm. So if you’re considering one of these products, look for second-generation devices. That said, these are screening tools. A negative result doesn’t guarantee your drink is safe, both because the strips have limits and because other substances used in drink-spiking would not be detected at all.

Precursor Drugs Complicate the Picture

GHB is not always consumed directly. Two legal or semi-legal industrial chemicals, gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), are rapidly converted into GHB in the body. GBL is converted almost instantly, with a half-life of about one minute for the conversion step.¹ 1,4-BD follows a similar but slightly slower path, being first metabolized by the same enzyme that processes alcohol before becoming GHB.¹²

From a testing standpoint, once conversion has occurred the body looks the same as if GHB had been taken directly. Standard toxicology tests cannot distinguish between GHB taken as GHB and GHB formed from a precursor. One practical wrinkle with 1,4-BD is that drinking alcohol simultaneously can actually slow its conversion, since both compounds compete for the same enzyme. That can shift the timing of peak GHB levels and potentially alter the detection window slightly. Researchers have shown that blocking this enzyme with the drug fomepizole dramatically reduced conversion of 1,4-BD to GHB, lowering peak GHB concentrations from about 50 to about 11 micrograms per milliliter.¹² That particular finding is clinically interesting for treating overdoses, but for someone wondering whether GBL or 1,4-BD exposure can be proven by a toxicology test, the answer is: only indirectly, by detecting the GHB they produce.

Sample Storage Can Create False Positives

Even after a sample is collected, the story isn’t over. GHB can be produced inside a blood sample after collection, a phenomenon called in vitro production. Bacteria and other processes in stored blood generate GHB from natural precursors, and concentrations can rise to forensically meaningful levels over time. In whole blood samples stored in liquid form at room temperature, GHB concentrations climbed substantially over 30 days. Even at refrigerator temperature, two out of 40 samples reached about 13 micrograms per milliliter, a level that could be mistaken for drug use.¹³

Post-mortem samples are even more problematic. In cases with no known GHB exposure, blood GHB levels in autopsy samples stored at room temperature rose from ranges of roughly 4 to 22 mg/L at collection to as high as 38 to 95 mg/L after 30 days.¹⁴ Freezing samples and using fluoride preservative prevents this artificial rise. One study found that samples from living persons stored at minus 20 degrees Celsius with fluoride showed a mean concentration change of less than one percent over time.¹⁵ Serum separated from whole blood also resisted in vitro production much better than liquid whole blood.¹³

This matters because a forensic result showing an elevated GHB level is only trustworthy if the sample was properly handled. Defense attorneys in GHB-related cases regularly challenge results on storage grounds. If you’re involved in any situation where forensic GHB evidence matters, whether as a victim, attorney, or clinician, confirming how the sample was stored is as important as the result itself.

Emerging Biomarkers That Might Extend the Window

Because GHB itself disappears so quickly, researchers have been hunting for metabolic byproducts that linger longer. The most promising candidates are phase-II metabolites, compounds the body creates when it chemically tags GHB for excretion. The two leading ones are GHB-glucuronide and GHB-sulfate.¹⁶

GHB-glucuronide was first identified in human urine in 2013. The reasoning behind its promise is straightforward: glucuronidated metabolites of other drugs generally stick around longer than the parent compound. The researchers who discovered it found concentrations ranging from about 0.1 to 5 micrograms per milliliter in clinical urine samples and proposed it as a biomarker that could extend the detection window for GHB intake.¹⁷ Beyond these conjugates, broader metabolic shifts after GHB exposure have been documented, including changes in compounds like glycolic acid, 3,4-dihydroxybutyric acid, and 2-hydroxyglutaric acid.¹⁸

None of these biomarkers have entered routine forensic practice yet. They’re research-stage tools that need further validation in larger populations before they can be used in court. But they represent the most active frontier in GHB detection science and could eventually make proving past exposure much more feasible, especially in drug-facilitated sexual assault cases where victims often don’t seek testing until well after the standard detection window has closed.

A Rare Genetic Condition That Mimics Chronic GHB Exposure

There is one medical situation where GHB levels are persistently elevated without any external drug use. Succinic semialdehyde dehydrogenase deficiency (SSADHD) is a rare inherited metabolic disorder in which the enzyme responsible for breaking down GABA malfunctions. This causes GABA and its byproduct GHB to accumulate in the brain and body fluids.⁸ People with SSADHD have chronically elevated GHB in their blood and urine, which can theoretically lead to a false-positive forensic result if the condition is not recognized.¹⁹ The condition is extremely rare and usually diagnosed in childhood based on developmental symptoms like low muscle tone, speech delay, and movement problems. It would be an extraordinarily unlikely explanation for an isolated elevated GHB finding in an otherwise healthy adult, but it illustrates how the endogenous production of GHB complicates forensic interpretation in unexpected ways.